Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
Despite numerous innovative treatment strategies, the treatment of glioblastoma (GB) remains challenging. With the current state-of-the-art therapy, most GB patients succumb after about a year. In the evolution of personalized medicine, targeted radionuclide therapy (TRT) is gaining momentum, for ex...
Main Authors: | Liesbeth Everix, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde, Julie Bolcaen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/7/1821 |
Similar Items
-
Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
by: Julie Bolcaen, et al.
Published: (2021-06-01) -
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
by: Liesbeth Everix, et al.
Published: (2023-02-01) -
The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute
by: Pascal V. Grundler, et al.
Published: (2020-12-01) -
7Be and 22Na radionuclides for a new therapy for cancer
by: Kukulin Vladimir I., et al.
Published: (2023-12-01) -
Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy
by: Sofia Koustoulidou, et al.
Published: (2021-03-01)